Supplementary Table 2. Baseline characteristics among individuals stratified by assignment in this sub-analysis

Characteristics	Aspirin (n=2,373)	Clopidogrel-aspirin (n=2,320)	*P*
Age (yr)	65.0 (57.0–71.0)	65.0 (57.0–71.0)	0.26
Male sex	1,471 (62.0)	1,514 (65.3)	0.02
Body mass index (kg/m^2)	24.5 (22.7–26.7)	24.4 (22.6–26.6)	0.18
Medical history			
Hypertension	1,590 (67.0)	1,581 (68.1)	0.40
Diabetes mellitus	656 (27.6)	631 (27.2)	0.73
Dyslipidemia	96 (4.0)	76 (3.3)	0.16
Previous ischemic stroke	714 (30.1)	681 (29.4)	0.58
eGFR <60 mL/min	113 (4.8)	93 (4.0)	0.21
Current smoking	658 (27.7)	675 (29.1)	0.30
Use of agents before qualifying event			
Aspirin	321 (13.5)	287 (12.4)	0.24
Clopidogrel	10 (0.4)	16 (0.7)	0.22
Lipid-lowering agent	234 (9.9)	218 (9.4)	0.59
Qualifying event			0.82
TIA	304 (12.8)	290 (12.5)	
Acute single infarction	472 (19.9)	449 (19.4)	
Acute multiple	1,597 (67.3)	1,581 (68.1)	
≥50% symptomatic stenosis			0.76
Yes	1,916 (82.4)	1,872 (82.1)	
No	409 (17.6)	409 (17.9)	
NIHSS score in qualifying ischemic stroke*			0.61
≤3	1,608 (77.7)	1,591 (78.4)	
4 or 5	461 (22.3)	439 (21.6)	
ABCD^2 score in qualifying TIA†			0.06
4 or 5	229 (75.3)	237 (81.7)	
>5	75 (24.7)	53 (18.3)	
Statin therapy‡			0.76
Immediate intensive statin	1,189 (50.1)	1,152 (49.7)	
Delayed intensive statin	1,184 (49.9)	1,168 (50.3)	
CYP2C19 LOF carriers			0.60
No LOF allele	1,010 (42.6)	959 (41.3)	
One LOF allele (intermediate metabolizer)	1,083 (45.6)	1,070 (46.1)	
Two LOF alleles (poor metabolizer)	280 (11.8)	291 (12.5)	

Values are presented as median (interquartile range) or n (%).
eGFR, estimated glomerular filtration rate; TIA, transient ischemic attack; NIHSS, National Institutes of Health Stroke Scale; ABCD^2, age, blood pressure, clinical features, duration of symptoms, and diabetes; LOF, loss-of-function.
*NIHSS score ranges from 0 to 42 for evaluating conditions of patients with ischemic stroke, and higher scores suggest more severe stroke; †ABCD^2 score ranges from 0 to 7, and higher scores suggest higher risk of stroke; ‡The immediate intensive statin and delayed intensive statin groups correspond to the factorial statin randomization arms of the Intensive Statin and Antiplatelet for Acute High-Risk Intracranial or Extracranial Atherosclerosis trial.

https://doi.org/10.5853/jos.2025.05092